Evidence map›Paper›PMID 30419851›Full record

ArticleBMC cancer2018

Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates.

Karen Couvreur, Eline Naert, Emiel De Jaeghere, Philippe Tummers, Amin Makar, Pieter De Visschere, Mieke Van Bockstal, Jo Van Dorpe, Wilfried De Neve, Hannelore Denys and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Transcriptomic analysis revealsOncology letters · 2024
    Article
  3. Article
  4. Article
  5. Immune infiltration could predict the efficacy of short-term radiotherapy in patients with cervical cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer.Cancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Karen CouvreurDepartment of Medical Oncology, UZ Gent, Ghent, Belgium.
Eline NaertDepartment of Medical Oncology, UZ Gent, Ghent, Belgium.
Emiel De JaeghereDepartment of Medical Oncology, UZ Gent, Ghent, Belgium.
Philippe TummersDepartment of Gynecology, UZ Gent, Ghent, Belgium.
Amin MakarDepartment of Gynecology, UZ Gent, Ghent, Belgium.
Pieter De VisschereDepartment of Radiology, UZ Gent, Ghent, Belgium.
Mieke Van BockstalDepartment of Pathology, UZ Gent, Ghent, Belgium.
Jo Van DorpeDepartment of Pathology, UZ Gent, Ghent, Belgium.
Wilfried De NeveDepartment of Radiation Oncology, UZ Gent, Ghent, Belgium.
Hannelore DenysDepartment of Medical Oncology, UZ Gent, Ghent, Belgium.
Katrien VandecasteeleDepartment of Radiation Oncology, UZ Gent, Ghent, Belgium. Katrien.vandecasteele@uzgent.be.ORCID http://orcid.org/0000-0002-7221-0811
Ghent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies on cervical cancer reported a worse outcome for adenocarcinoma (AC) compared with squamous cell carcinoma (SCC). Nevertheless, standard treatment remains identical. Insight in the impact of histological types on biological behavior and pathological complete response rates might result in a treatment paradigm shift.

methodsClinicopathological characteristics, survival rates and relapse patterns were compared between AC (n = 36) and SCC (n = 143) cervical cancer patients. Pathological response to treatment was evaluated in the patient subgroup treated with neo-adjuvant chemoradiation followed by surgery (NA-CRT group; n = 84).

resultsIn the entire cohort, 5y Disease Specific Survival (DSS) was 97.1 and 84% for AC and SCC respectively (p = 0.150). In the NA-CRT group 5y DSS was 100 and 75.5% for AC and SCC respectively (p = 0.059). Relapse patterns did not differ significantly between AC and SCC in the entire cohort, or in the NA-CRT group. Adenocarcinoma patients treated with NA-CRT showed significantly less pathological complete response compared with SCC patients (AC = 7%, SCC = 43%, p = 0.027).

conclusionsThere were no statistically significant differences regarding relapse and DSS rates between SCC and AC in the entire cohort, or the NA-CRT group. However, a trend to better 5y DSS of AC in the NA-CRT group was observed. This analysis showed significant differences in treatment responses after NA-CRT: patients with AC responded remarkably less to chemoradiation, resulting in a significantly lower pathological complete response rate. These findings imply a need for a paradigm shift in the treatment of cervical AC patients.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Squamous CellFemaleHumansLymph NodesMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingPrognosisRecurrenceRetrospective StudiesTreatment OutcomeUterine Cervical NeoplasmsAdenocarcinomaCervical cancerDifferencesPrognosisSquamous cell carcinomaSurvival

Identifiers

PMID30419851
PMCPMC6233604
OpenAlexW2901632606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.